论文部分内容阅读
本文报道用乙型肝炎免疫球蛋白(HBIG)预防母婴传播乙型肝炎病毒的初步效果。对129例HBsAg阳性携带母亲的婴儿进行对照研究,在64例试验组内用HBIG多次被动免疫新生儿,用酶标检测技术;观察半年,只有12例为HBsAg阳性(18.75％)。而在65例对照组内,婴儿HBsAg阳性数为32例(49.23％),两组婴儿HBsAg阳性率差别有极显著意义(P<0.001)。另外在试验组中有20例母亲为HBeAg阳性,6个月内只有7例婴儿为HBsAg阳性(35％),而对照组有21例母亲为HBeAg阳性,其婴儿有19例是HBsAg阳性(90.48％)。两组婴儿HBsAg阳性率差别也有极显著意义(P<0.001)。本结果初步表明:用1∶2048(PHA)的国产HBIG预防母婴乙型肝炎病毒(HBV)传播具有良好的近期效果。
This article reports the initial effect of hepatitis B immunoglobulin (HBIG) in preventing mother-to-child transmission of hepatitis B virus. A control study of 129 HBsAg-positive mothers in infants was performed. Multiple immunization of newborns with HBIG in 64 experimental groups was performed by enzyme-linked immunosorbent assay (ELISA). Only half of HBsAg-positive patients (18.75%) were observed in six months. In 65 cases of control group, the positive number of HBsAg in infants was 32 cases (49.23%). There was significant difference between the two groups in the positive rate of HBsAg (P <0.001). In addition, 20 mothers in the test group were HBeAg positive, with only 7 infants HBsAg positive (35%) in 6 months compared with 21 HBeAg mothers in the control group and 19 infants HBsAg positive (90.48 %). There was also a significant difference in the positive rates of HBsAg between the two groups (P <0.001). The preliminary results show that: 1: 2048 (PHA) of domestic HBIG to prevent the transmission of hepatitis B virus (HBV) has a good near-term results.